

McLoughlin Dennis  
Form 3  
September 07, 2018

# FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*

McLoughlin Dennis

(Last) (First) (Middle)

C/O PACIRA  
PHARMACEUTICALS,  
INC., 5 SYLVAN WAY,  
SUITE 300

(Street)

PARSIPPANY, NJ 07054

(City) (State) (Zip)

2. Date of Event Requiring Statement

(Month/Day/Year)

08/29/2018

3. Issuer Name and Ticker or Trading Symbol  
Pacira Pharmaceuticals, Inc. [PCRX]

4. Relationship of Reporting Person(s) to Issuer

5. If Amendment, Date Original Filed(Month/Day/Year)

(Check all applicable)

☐ Director ☐ 10% Owner

☒ Officer ☐ Other

(give title below) (specify below)

Chief Commercial Officer

6. Individual or Joint/Group Filing(Check Applicable Line)  
☒ Form filed by One Reporting Person  
☐ Form filed by More than One Reporting Person

### Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security  
(Instr. 4)

2. Amount of Securities Beneficially Owned  
(Instr. 4)

3. Ownership Form:  
Direct (D)  
or Indirect (I)  
(Instr. 5)

4. Nature of Indirect Beneficial Ownership  
(Instr. 5)

Common Stock

14,833 <sup>(1)</sup>

D A

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security  
(Instr. 4)

2. Date Exercisable and Expiration Date  
(Month/Day/Year)

3. Title and Amount of Securities Underlying Derivative Security

4. Conversion or Exercise

5. Ownership Form of

6. Nature of Indirect Beneficial Ownership  
(Instr. 5)

# Edgar Filing: McLoughlin Dennis - Form 3

|                             | Date<br>Exercisable | Expiration<br>Date | (Instr. 4)<br>Title | Amount or<br>Number of<br>Shares | Price of<br>Derivative<br>Security | Derivative<br>Security:<br>Direct (D)<br>or Indirect<br>(I)<br>(Instr. 5) |   |
|-----------------------------|---------------------|--------------------|---------------------|----------------------------------|------------------------------------|---------------------------------------------------------------------------|---|
| Stock Option (Right to Buy) | Â (2)               | 07/03/2028         | Common Stock        | 20,000                           | \$ 33.1                            | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 06/13/2028         | Common Stock        | 47,250                           | \$ 38.35                           | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 06/14/2027         | Common Stock        | 6,000                            | \$ 44.2                            | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 06/02/2027         | Common Stock        | 10,000                           | \$ 44.1                            | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 02/02/2027         | Common Stock        | 3,000                            | \$ 41.9                            | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 12/07/2026         | Common Stock        | 6,000                            | \$ 32.35                           | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 06/15/2026         | Common Stock        | 2,400                            | \$ 40.34                           | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (2)               | 06/03/2025         | Common Stock        | 3,500                            | \$ 79.43                           | D                                                                         | Â |
| Stock Option (Right to Buy) | Â (3)               | 01/03/2024         | Common Stock        | 10,623                           | \$ 56.32                           | D                                                                         | Â |

## Reporting Owners

| Reporting Owner Name / Address                                                                           | Relationships |           |                            |       |
|----------------------------------------------------------------------------------------------------------|---------------|-----------|----------------------------|-------|
|                                                                                                          | Director      | 10% Owner | Officer                    | Other |
| McLoughlin Dennis<br>C/O PACIRA PHARMACEUTICALS, INC.<br>5 SYLVAN WAY, SUITE 300<br>PARSIPPANY, NJ 07054 | Â             | Â         | Â Chief Commercial Officer | Â     |

## Signatures

/s/ Kristen Williams,  
Attorney-in-Fact

09/07/2018

\*\*Signature of Reporting Person

Date

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes 11,162 unvested restricted stock units. The unvested restricted stock units vest as follows: (i) 437 restricted stock units that vest on June 3, 2019, (ii) 600 restricted stock units that vest in two equal annual installments on June 3, 2019 and June 3, 2020, (iii) 2,250 restricted stock units that vest in three equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021, and (iv) 7,875 restricted stock units that vest in four equal annual installments on June 3, 2019, June 3, 2020, June 3, 2021 and June 3, 2022, in each case provided

## Edgar Filing: McLoughlin Dennis - Form 3

that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.

The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to

- (2) the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.

- (3) The stock options are fully vested.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.